Mouth Disorders
Also known as: Mouth, Buccal, Oral, Syrinx
Methodology & AI Transparency ⓘ
Mouth Disorders Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Your mouth is one of the most important parts of your body.
- 2 Real-world patient consensus: Clinical coding for Mouth Disorders uses ICD-10 K13.70 across ENT & Hearing specialty care.
- 3 Typical cash cost range: Differential triage of Mouth Disorders (K13.70) utilizes hearing protection/amplification [Mouth Disorders K13.70].
- 4 Top reported side effects / signs: Objective lab/clinical target for Mouth Disorders: Periodontal Pocket Depth in Mouth Disorders (K13.70: & Bleeding Index) (Probing <= 3 mm without bleeding (K13.70)) and Pure-Tone Audiometry & in Mouth Disorders (K13.70: Tympanometry).
Ask our AI Specialists anything about Mouth Disorders
What Is Mouth Disorders?
Your mouth is one of the most important parts of your body. It has many different functions. It allows you to: Take in food and drink Breathe in air Start digestion, with your teeth chewing the food you eat and your salivary glands releasing saliva to help break down the food Speak and sing Show emotion, by smiling or pouting Any problem that affects your mouth can make it hard to eat, drink, or even smile.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Mouth Disorders (ICD-10 K13.70) is driven by or subgingival bacterial in Mouth Disorders (K13.70: biofilm triggering periodontal); Cross-referenced with NIH MeSH (Mouth Diseases), specialists in Ear, Nose, Throat & Oral Health monitor Pure-Tone Audiometry & in Mouth Disorders (K13.70: Tympanometry) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Take in food and drink
- • Start digestion, with your teeth chewing the food you eat and your salivary glands releasing saliva to help break down the food
- • Presentation of Mouth Disorders (K13.70): bleeding or receding in Mouth Disorders (K13.70: gums, tooth sensitivity,)
- • Secondary Mouth Disorders clinical sign: muffled hearing, ear in Mouth Disorders (K13.70: fullness, popping pressure,)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Mouth Disorders Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | K13.70 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Ear, Nose, Throat & Oral Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Periodontal Pocket Depth in Mouth Disorders (K13.70: & Bleeding Index) | Probing <= 3 mm without bleeding (K13.70) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Pure-Tone Audiometry & in Mouth Disorders (K13.70: Tympanometry) | Thresholds <= 20 dB HL; normal middle-ear pressure (K13.70) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Mouth Disorders
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Dyclonine Hydrochloride Dyclopro, Sucrets Sore Throat Wild Cherry • RxCUI 1048281 | FDA Prescription Therapeutic Agent | 81% | $0.2800 | $ 19.84 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Mouth Disorders)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Does "wearing off" of efficacy occur in galcanezumab-treated patients at the end: What a 2,680-Participant Study Found Consistent with previous analyses at the population-level that showed no evidence of decreased efficacy at the end of a treatment cycle, rates of individual patients meeting the threshold of "wearing off" in this analysis were... Headache • 2022-02-15 • Phase III Randomized Trial | N = 2,680 | 96/100 | PMID 35076090 ↗ |
| New Insights on Long-term real-world benefits and safety of ixekizumab: A 5-year analysis of the: What a 1,346-Participant Study Found IXE demonstrates sustained efficacy and consistent safety through 264 weeks in patients using the approved dose. Journal of the American Academy of Dermatology • 2021-08-15 • Phase III Randomized Trial | N = 1,346 | 96/100 | PMID 33253833 ↗ |
| New Insights on Efficacy of Risankizumab across distinct PsA phenotypes identified with machine: What a 1,119-Participant Study Found Five distinct PsA phenotypes were identified in patients starting risankizumab. Arthritis research & therapy • 2025-11-29 • Phase III Randomized Trial | N = 1,119 | 90/100 | PMID 41318485 ↗ |
| Can This Approach Help? Inside the Latest Research on Long-term protection of an inactivated enterovirus type 71 vaccine against hand, Under the current EV71 epidemic conditions in China, the two-dose regimen of the inactivated EV71 vaccine provides durable protection exceeding 72% for at least 20 years. Vaccine • 2026-03-19 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41650673 ↗ |
| Can This Approach Help? Inside the Latest Research on 0.1% octenidine mouthwash on plaque re-growth in healthy adults: a multi-center OCT 0.1% mouthwash inhibits plaque formation over 5 days. Clinical oral investigations • 2021-07-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 33483868 ↗ |
Mouth Disorders Patient Community & “People Like Me” Threads
Filter Mouth Disorders community threads and patient logs by age, biological sex, dosage, and treatment duration.